Fisher & Paykel Healthcare Corporation Limited · NZX:FPH
Fisher & Paykel Healthcare — Shareholder Meeting (2004)
17 slides from Fisher & Paykel Healthcare's shareholder meeting presentation, 2004
Slide 1: Fisher & Paykel Healthcare
Fisher<é.Paykel HEALTHCARE Fisher éPaykel HEALTHCARE
Slide 2: FY04 Highlights
FY04 Highlights • Operating revenue up 28% to US$132M, 3% to NZ$215M • Operating profit up 33% to US$49M, 7% to NZ$79M • Operating margin of 36.8% • Pre-tax return on average shareholders’ equity of 42% • R&D investment increased to 6.6% of revenue 2 2
Slide 3: Sales by Product Group
Sales by Product Group FY04 Warming & Neonatal Care Distributed 7% 4% OSA Respiratory 37% Humidification 52% 3
Slide 4: Sales by Region
Sales by Region FY04 Asia Pacific Other 22% 4% North Europe America 30% 44% 4 4
Slide 5: Expanding Global Presence
Expanding Global Presence 5 5
Slide 6: Respiratory Humidification
Respiratory Humidification 6 6
Slide 7: Respiratory Humidification
Respiratory Humidification • Revenue growth US$ FY04 +34%, underlying growth approx 14% • SARS § US$2M • Sales growth driven by chamber and circuit sales, MR850 share gains • Continued market share growth in breathing circuits 7 7
Slide 8: Respiratory Humidification
Respiratory Humidification • Revolutionary dry tube technology introduced • Non-invasive ventilation circuit, weaning kit, catheter mount introduced • Filters growing strongly – adding value per patient • New humidifier systems in R&D pipeline 8 8
Slide 9: Dry Tube Technology
Fisher éPaykel HEALTHCARE
Slide 10: New Market Opportunities
New Market Opportunities • COPD project • Humidification system for laparoscopic insufflation MR860 Humidifier system for laparoscopic insufflation 10 10
Slide 11: Obstructive Sleep Apnea
Obstructive Sleep Apnea 11 11
Slide 12: Obstructive Sleep Apnea
Obstructive Sleep Apnea • Flow generator and mask revenue growth US$ FY04 +35%, 2H04 +45% • Total revenue growth US$ FY04 +17% • HC221LE flow generator introduced • HC211 convertible flow generator introduced, expands market opportunity 12 12
Slide 13: New masks
New masks HC407 FlexiFit™ Nasal Mask HC431 FlexiFit™ Full Face Mask 13 13
Slide 14: Neonatal
Neonatal • Revenue growth US$ FY04 +63% • Strong infant warmer revenue growth, favourable customer mix • Growing acceptance of Neopuff infant resuscitator and neonatal CPAP system • Increasing consumable revenue IW930 Cosycot Infant Warmer 14 14
Slide 15: Neonatal
Neonatal RD900 Neopuff Infant Resuscitator Neonatal Breathing System 15 15
Slide 16: Patient Warming
Patient Warming Introduced second generation patient warmer with proprietary single use sensor. 16 16
Slide 17: Fisher & Paykel Healthcare
Fisher & Paykel HEALTHCARE Fisher & Paykel HEALTHCARE
Fisher & Paykel Healthcare — Shareholder Meeting (2004) on 6ix